Hellek Bråthen

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.

Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.

Agrinos AS engages in the development, production, and trade of biological crop inputs. Its products include iNvigorate, B-Sure, and Agrinos 5-0-0. The firm focuses on core crops such as corn, potatoes, soybeans, sugarcanes, tomatoes, and wheat; and regional crops such as verries, citrus and fruit trees, coffee, cotton, forage, leafy greens, and vegetables. The company was founded by Kjetil Langland Bøhn, Karl Reiner Fick Rochin, and Aaron Powers in 2009 and is headquartered in Oslo, Norway.